

UNCLASSIFIED

AD NUMBER
ADB257696
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info; Aug 99. Other requests shall be referred to USAMRMC, Ft Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, dtd 21 Feb 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Grant Number DAMD17-96-1-6123

TITLE: Design, Synthesis, and Testing of Breast Cancer
Angiogenesis Inhibitors

PRINCIPAL INVESTIGATOR: Edward L. Schwartz, Ph.D.

CONTRACTING ORGANIZATION: Montefiore Medical Center
Bronx, New York 10467

REPORT DATE: August 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, Aug 99). Other requests
for this document shall be referred to U.S. Army Medical Research
and Materiel Command, 504 Scott Street, Fort Detrick, Maryland
21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20000907 133

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-96-1-6123

Organization: Montefiore Medical Center

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 1999	3. REPORT TYPE AND DATES COVERED Annual (15 Jul 98 - 14 Jul 99)	
4. TITLE AND SUBTITLE Design, Synthesis, and Testing of Breast Cancer Angiogenesis Inhibitors			5. FUNDING NUMBERS DAMD17-96-1-6123	
6. AUTHOR(S) Edward L. Schwartz, Ph.D				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Montefiore Medical Center Bronx, NY 10467			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only proprietary information, Aug 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) Tumor angiogenesis is the process by which a growing tumor mass recruits the new blood vessels required for its continued growth, and through which the tumor can spread to distant sites. This proposal focuses on the development of inhibitors of a particular angiogenic factor, thymidine phosphorylase, by targeting the enzymatic activity of TP, since it has been found to be required for angiogenesis. In the past year, several compounds were synthesized as potential TP inhibitors, including one having high potency as an enzyme inhibitor ($IC_{50} = 180$ nM). TP was found to induce human endothelial cell migration <i>in vitro</i> , a process found to require both a TP gradient and the presence of thymidine. The TP-mediated endothelial cell migration was blocked by TP inhibitors, and this was found to be specific in that the actions of a different angiogenic factor, VEGF (vascular endothelial cell growth factor), were not blocked.				
14. SUBJECT TERMS Breast Cancer Angiogenesis Thymidine phosphorylase			15. NUMBER OF PAGES 17	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

_____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

_____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

✓ _____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

_____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

_____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

_____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

_____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

 8/31/99

PI - Signature Date

Table of Contents


Report documentation page	2
Foreward	3
Table of contents	4
Introduction	5
Body of report	6-14
Conclusion	15
References	15-16

Introduction. There is a need for alternative approaches to treat metastatic breast cancer. One rapidly developing area of investigation is the study of tumor angiogenesis, the process by which a growing tumor mass recruits the new blood vessels required for its continued growth, and through which the tumor can spread to distant sites.¹⁻² Most studies have demonstrated the importance of angiogenesis in the progression of human breast malignancies and found the extent of vascularization to be correlated with tumor size, frequency of metastasis, and poor prognosis.³⁻⁸ Several polypeptides and growth factors that are produced by breast cancer epithelial and stromal cells have been identified as having endothelial cell mitogenicity and angiogenic activity.^{1,9} Our studies are focusing on the angiogenic factor PD-ECGF, based on recent evidence demonstrating its role in experimental and human cancer, and the finding that PD-ECGF is identical to human thymidine phosphorylase (TP).¹⁰⁻¹² When transfected into NIH 3T3 cells, TP was found to increase the vascularization of tumors growing in nude mice after sc inoculation.¹³ Similarly, overexpressing TP in MCF7 breast carcinoma cells markedly increased tumor growth *in vivo*, although it had no effect on the growth of the cells *in vitro*.¹⁴ Western blot analysis of primary human breast tissue showed that TP expression was elevated in the tumors compared to the normal tissue¹⁴, a finding which provides clinical relevance to the transfection experiments. Studies suggest that the angiogenic and endothelial cell chemotactic activities of PD-ECGF are dependent upon its enzymatic activity, and this has been confirmed with site-directed mutagenesis studies.^{14,15-17} Of the angiogenic factors identified to date, TP is the only one in which an enzymatic activity of the factor is required for angiogenic activity. These observations serve as the basis for our hypothesis that inhibition of the catalytic activity of TP will also block its angiogenic properties. The purpose of this study is to design and synthesize highly potent inhibitors of TP enzymatic activity, and determine their antiangiogenic and antitumor activities in *in vitro* and *in vivo* model systems.

Technical objective 1: Synthesis of inhibitors of TP.

Our original proposal suggested the synthesis of four structurally distinct classes of pyrimidines or pyrimidine nucleosides for evaluation as potential TP inhibitors (**I-IV** shown in Fig. 1). In view of some significant new developments in the area of inhibitors as antiangiogenic agents we had also incorporated in last years report a new series of analogs (**class V**) which were structurally similar to **class I** but required separate synthetic methodologies.


FIGURE 1.



We describe below progress during the previous year towards completion of the five targeted classes of compounds.


We had already reported earlier on the synthesis of several new derivatives of **class I** (see Fig.1, $R' = \text{H}$, $R'' = \text{substituted phenyl derivatives}$) which exhibited moderate TP inhibitory activities, with IC_{50} values in the range of 30 - 275 μM . Halogenation of the 5-position of these compounds was attempted in order to obtain those targets where $R' = \text{Cl or Br}$ since, as was described in the original application, it is anticipated that such derivatives would exhibit enhanced activities because of their closer stereoelectronic resemblance to thymine. In most instances, chlorination or bromination at C-5 was also accompanied by partial halogenation of the phenyl substituent at C-6 thus affording complex mixtures of products. It was decided therefore to prepare the desired 5-halogenated derivatives by reaction of already 5-halogenated 6-chlorouracil intermediates (such as **2-2**, in fig 2) with the appropriate amines as we originally suggested as a back-up approach. As illustrated in figure 2, work is now in progress for the halogenation of 6-chlorouracil **2-1** (readily accomplished via known procedures) and for the displacement of the 6-chloro function by various anilino and other amines (as already carried out for derivatives with $R' = \text{H}$).

FIGURE 2.



Access to the targeted 5',6-cyclouridine derivatives of **class II** by selective reduction of the azido function of intermediate **3-1** (Fig. 3) to give **3-4** has also been attempted in the expectation that this product could be made to undergo addition-elimination to the final desired product **3-2**. Catalytic hydrogenation over Pd/C however was found to give **3-3** undoubtedly produced by the concurrent hydrogenolytic debromination at C-5. The desired product **3-2** (soon to be tested for biological activity) could be obtained, albeit in poor yields, by reduction of **3-1** with triphenyl phosphine. Its formation, however, was accompanied by several undesirable by-products. A more promising strategy therefore lies in the bromination of **3-3** (more readily obtained by the direct 5'-azidation of 2'-deoxyuridine) to afford **3-4** and, after ring closure, **3-2**. The latter would then serve as the major intermediate to all remaining targets (**3-5** or **3-6**) as outlined in fig. 3. An attractive alternate route to the desired 5-Me derivative **3-6** (reported in the literature by A. Matsuda and associates) may also be employed. It is based on displacement of the 5'-O-tosyl function of thymidine derivative **3-7** by azide followed by an *in situ*, thermally induced 1,3-dipolar cycloaddition of the azido


FIGURE 3.



function onto the 5,6 pyrimidine double bond and spontaneous elimination of N₂. Work is now in progress to achieve these goals.


As we had reported earlier, the thymidine analog **4-4** which is the major representative of **class III** had been synthesized as outlined in fig. 4 and was found to be inactive. Efforts have been expended in the past year to resynthesize key intermediate **4-3** so as to be able to make new derivatives with groups other than the N-methyl to be assayed for enhanced activity. This work is now in progress.

FIGURE 4.



We had reported earlier on the synthesis of compound **5-2** (fig. 5), a key intermediate in the projected synthesis of the members of **class IV**. Further efforts to utilize it for subsequent functionalization of the side chain at C-4' have been thwarted by its relative instability and the length of the multistep procedure required to obtain it. We have therefore begun to exploit an alternative approach based on the recently reported regio- and stereospecific method for introducing a 2-hydroxyethyl group as a C-4' carbon-branched function in thymidine (**5-1**). The method (outlined in fig. 5) utilizes the 4'-(phenylseleno)thymidine derivative **5-3** (prepared in several high yielding steps from thymidine) for introducing a dimethylvinylsilyl group as a radical acceptor tether (as in **5-6**) followed by a free radical reaction (Bu₃SnH/AIBN) and a Tamao oxidation to give the desired product **5-8**. The latter is ideally suited as synthetic substitute for intermediate **5-2** since its primary hydroxyl function can undergo selective functionalization either directly or indirectly to an aldehyde followed by further extension via a Wittig reaction (or a Horner modification) to afford the desired phosphonates or carboxylates proposed as targets of **class IV**.

FIGURE 5.



The largest portion of our efforts have been spent on the synthesis of new members of class V, because the most active inhibitors of TP known to date belong to this class of uracil analogues. Table 1 tabulates a new set of compounds prepared recently. All were prepared in 60-90% yields by reacting the corresponding 5-substituted (R=H, Me, Cl) 6-chloromethyluracil with a 1.5-2 fold molar excess of the amine in refluxing methanol for 3-4 hrs. Addition of HCl gas to the precipitated product and filtration afforded the hydrochloride form while neutralization with aqueous sodium bicarbonate afforded the free base form. A recent report confirmed the activity of a different (but structurally related) TP inhibitor which also had antitumor activity *in vivo*¹⁸.

Technical objective 2: Evaluation of target compounds as TP inhibitors and for effects on endothelial cells.


TP activity was measured in assays which contained 0.2 M KH₂PO₄ (pH 7.8), 0.2 mM [5'-³H] thymidine (1 μCi), human TP (5 ng), and several different concentrations of the inhibitor being tested. Reactions were stopped after 30 min at 37° by the addition of ice-cold TCA containing activated charcoal. After centrifugation, an aliquot of the supernatant was counted in a liquid scintillation counter. IC₅₀ values for each compound shown in Table 1 were calculated from data from at least 3 determinations.

Table 1.

Structure Activity Relationship of some Cpds
of **Class V** Uracil Derivatives as TP Inhibitors
prepared in our laboratories (F.W. / form and
activity against the human enzyme)


R \ R'				
H	192.17 (Free base) IC ₅₀ ~ 300 μM	195.22 (Free base) IC ₅₀ ~ 300 μM	260.69 (HCl salt) IC ₅₀ ~ 200 μM	262.71 (HCl salt) IC ₅₀ ~ 300 μM
CH₃	206.20 (Free base) IC ₅₀ ~ 300 μM	209.24 (Free base) IC ₅₀ ~ 5 μM	274.72 (HCl salt) IC ₅₀ ~ 400 μM	276.74 (HCl salt) IC ₅₀ ~ 200 μM
Cl	263.08 85-32 (HCl salt) IC ₅₀ ~ 190nM	—	295.14 (HCl salt) IC ₅₀ ~ 300 μM	—

Recently reported
activities of structurally
similar analogs



We have also begun our studies with human umbilical vein endothelial cells (HUVEC) in an endothelial cell migration assay. Initial experiments to optimize and characterize the culture system and response to TP are shown below.


FIGURE 6 (next page). Dose dependent induction of HUVEC migration by TP. Human umbilical vein endothelial cells (isolated immediately prior to use) were cultured in the top well of 24 well plates which had an 8 micron pore size polycarbonate, collagen-coated, filter cell culture insert. TP or VEGF (vascular endothelial cell growth factor; used as a positive control) were added to the bottom chamber were added at the indicated concentrations. After 4 hours at 37°, cells on the bottom of the filters (i.e. endothelial cells which had migrated through the pores) were fixed, stained, and counted manually under a microscope. Data for all figures are means ± SD.



Conclusion: TP induces endothelial cell migration in a concentration-dependent manner.


In the next two series of experiments, we further characterized the mechanism for the stimulation of endothelial cell migration by TP. In the experiments shown in Figure 7, the TP was added at the same concentration as in Figure 6, but it was added to both sides of the chamber, thereby retaining TP enzyme activity but eliminating the gradient for TP. VEGF and FGF2 (bFGF or basic fibroblast growth factor) were included as controls in these experiments. As shown in Fig. 7, no migration of endothelial cells was seen when the gradients for TP or VEGF were eliminated, confirming that the nature of the migration induced can be described as chemotactic. In contrast, FGF was active both in the presence and absence of a gradient, indicating its action is to induce increased chemokinetic rather than chemotactic activity.

Figure 7 (next page). TP is a chemotactic mediator of endothelial cell migration. Experiments were carried out with HUVEC cells as described in the legend to figure 6, except in instances in which TP was added to both the top and bottom wells of the chambers (labeled "(-) grad"). VEGF and FGF2 were added to separate wells as controls.




We also evaluated the role of thymidine in the actions of TP. All experiments shown in Figs. 6 & 7 were done in medium containing 1% serum, which contains thymidine at a concentration between 5 and 10 μ M. When the serum was first treated with charcoal to remove the thymidine (CSS or charcoal-stripped serum in Fig. 8), the actions of TP were eliminated. Full migration-inducing activity could be restored to the CSS, however, by the addition of thymidine to a final concentration of 100 nM, equivalent to that found in medium containing 1% serum. We conclude from this experiment that thymidine must be present for TP to exert its actions. In contrast, VEGF induction of migration was not attenuated when CSS was used, indicating that thymidine or other molecules which bound to charcoal were not required for its actions.

FIGURE 8. TP requires thymidine to stimulate endothelial cell migration. Experiments were carried out with HUVEC cells as described in the legend to figure 6, except in instances in which charcoal-stopped serum (CSS) was used in place of 1% fetal bovine serum. TP was added to bottom wells of the chambers at a concentration of 10 ng/ml, and thymidine was used when indicated at a concentration of 100 nM.



Having confirmed the ability of TP to induce endothelial cell migration, we next examined the effect of one of the inhibitors which we had synthesized (5-chloro-6(1-imidazolylmethyl) uracil hydrochloride; structure 85-32 in Table 1, above). We found that 85-32 inhibited in a concentration-dependent manner the TP-mediated induction of endothelial cell migration. The inhibition was specific for TP, as 85-32 had no effect on VEGF-mediated chemotaxis.

Figure 9. Dose-dependent inhibition of TP-mediated endothelial cell migration by 85-32. These assays were done as above (legend to Fig. 6) with 100 ng/ml TP or 10 ng/ml VEGF and increasing concentrations of 85-32 (5 - 300 μ M), as indicated. Control wells were without TP or VEGF.



Technical objective 3: *In vivo* assays. We have begun experiments toward this objective. MCF7 human breast carcinoma cells were transfected with a cDNA for either human TP (clone pCMV-TPneo) or a control vector (pCMV-neo1) with the use of lipofectamine. Cells were cloned in the presence of G418 (geneticin), and after several weeks, individual clones were selected and expanded in liquid culture in the continuous presence of G418. These stably transfected cell lines were evaluated for TP mRNA expression, and one high-expressing line was selected for further study. In the figure to the right are shown the result of a RT-PCR analysis of RNA from control MCF7 cells (left lane), MCF7 cells transfected with the control vector (middle lane), or MCF7 cells transfected with the TP-containing vector (right lane). The lower bands are the fragments corresponding to the TP cDNA, and the upper bands are a GAPDH-fragment, used as a control.

We have recently begun an experiment in which the stably-transfected MCF7 cells (10^6 cells) containing either the control or TP vector were injected into the mammary fat pad of groups of Balb/c nude mice. We are now monitoring these mice for tumor growth.



Conclusions. A number of inhibitors of TP have been synthesized, including one (85-32) which is relatively potent ($K_i < 200$ nM). This compound can serve as a starting point to synthesize analogs to try to further increase TP-inhibitory potency. An *in vitro* assay of human endothelial cell migration in response to TP has been well characterized, and 85-32 has been shown to be active in this assay. This assay will continue to be utilized to identify new TP inhibitors and to further define their mechanisms of action. *In vivo* studies have begun and will eventually be used to evaluate the TP inhibitors under development.

REFERENCES

1. Folkman J and Shing Y (1992) Angiogenesis. *J. Biol. Chem.* 267:10931-10934.
2. Hayes DF (1994) Angiogenesis and breast cancer. *Hematology-Oncology Clinics of North America* 8:51-71.
3. Weidner N, Semple, JP, Welch WR and Folkman J (1991) Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. *N. Engl. J. Med.* 324:1-8.
4. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniowska K and Harris AL (1993) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. *Lancet* 340:1120-1124.
5. Toi M, Kashitani J and Tominaga T (1993) Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. *Int. J. Cancer* 55:371-374.
6. Gasparini G, Weidner N, Bevilacqua P. et. al. (1994) Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. *J. Clin. Oncol.* 12:454-466.
7. Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL (1994) tumor angiogenesis in node-negative breast carcinomas- relationship with epidermal growth factor receptor, estrogen receptor, and survival. *Breast Cancer Res. Treat.* 29:109-116.
8. Craft PS and Harris AL (1994) Clinical prognostic significance of tumor angiogenesis. *Annals of Oncology* 5:305-311.
9. Hlatky L, Tsionou C, Hahnfeldt P and Coleman CN (1994) Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. *Cancer Res.* 54:6083-6086.
10. Moghaddam A and Bicknell R (1992) Expression of PD-ECGF factor in *E. coli* and confirmation of its thymidine phosphorylase activity. *Biochemistry* 31:12141-12146.

11. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S-I, Fukui K, Ishizawa M and Yamada Y (1992) Angiogenic factor. *Nature* 356:668.
12. Sumizawa T, Furukawa T, Haraguchi M, Yoshimura A, Takeyasu A, Ishizawa M, Yamada Y and Akiyama S-I (1993) Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. *J. Biochem.* 114: 9-14.
13. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W and Heldin C-H (1989) Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. *Nature* 338: 557-562.
14. Moghaddam A, Zhang H-T, Fan T-P D, Hu D-E, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL and Bicknell R (1995) Thymidine phosphorylase is angiogenic and promotes tumor growth. *Proc. Nat. Acad. Sci.* 92:998-1002.
15. Haraguchi M, Miyadera K, Uemura K, Sumizawa T, Furukawa T, Yamada K, Akiyama S-I, and Yamada Y (1992) Angiogenic activity of enzymes. *Nature* 368:198-199.
16. Finnis C, Dodsworth N, Pollitt CE, Carr G and Sleep D (1993) Thymidine phosphorylase activity of platelet-derived endothelial cell growth factor is responsible for endothelial cell mitogenicity. *Eur. J. Biochem.* 212:201-210.
17. Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y and Akiyama S (1995) Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase. *Cancer Res.* 55:1687-1690.
18. Matsushita S, Nitanda T, Furukawa T, Sumizawa T, Tani A, Nishimoto K, Akiba S, Miyadera K, Fukushima M, Yamada Y, Yoshida H, Kanzaki T and Akiyama S (1999) The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. *Cancer Res.* 59:1911-1916, 1999.



DEPARTMENT OF THE ARMY

US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

21 Feb 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218


SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB263458	ADB282838
ADB282174	ADB233092
ADB270704	ADB263929
ADB282196	ADB282182
ADB264903	ADB257136
ADB268484	ADB282227
ADB282253	ADB282177
ADB282115	ADB263548
ADB263413	ADB246535
ADB269109	ADB282826
ADB282106	ADB282127
ADB262514	ADB271165
ADB282264	ADB282112
ADB256789	ADB255775
ADB251569	ADB265599
ADB258878	ADB282098
ADB282275	ADB232738
ADB270822	ADB243196
ADB282207	ADB257445
ADB257105	ADB267547
ADB281673	ADB277556
ADB254429	ADB239320
ADB282110	ADB253648
ADB262549	ADB282171
ADB268358	ADB233883
ADB257359	ADB257696
ADB265810	ADB232089
ADB282111	ADB240398
ADB273020	ADB261087
ADB282185	ADB249593
ADB266340	ADB264542
ADB262490	ADB282216
ADB266385	ADB261617
ADB282181	ADB269116
ADB262451	
ADB266306	
ADB260298	
ADB269253	
ADB282119	
ADB261755	
ADB257398	
ADB267683	
ADB282231	
ADB234475	
ADB247704	
ADB258112	
ADB267627	